Yanrong Zhu Selected Research

3,4-dihydroxyphenyllactic acid

12/2021	[Corrigendum] Synergistic cardioprotective effects of Danshensu and hydroxysafflor yellow A against myocardial ischemia-reperfusion injury are mediated through the Akt/Nrf2/HO-1 pathway.
7/2016	Synergistic cardioprotective effects of Danshensu and hydroxysafflor yellow A against myocardial ischemia-reperfusion injury are mediated through the Akt/Nrf2/HO-1 pathway.
2/2015	Neuroprotective effect and underlying mechanism of sodium danshensu [3-(3,4-dihydroxyphenyl) lactic acid from Radix and Rhizoma Salviae miltiorrhizae = Danshen] against cerebral ischemia and reperfusion injury in rats.
1/2013	Cardioprotective effect of Danshensu against myocardial ischemia/reperfusion injury and inhibits apoptosis of H9c2 cardiomyocytes via Akt and ERK1/2 phosphorylation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yanrong Zhu Research Topics

Disease

12	Reperfusion Injury 12/2021 - 01/2013
9	Myocardial Ischemia (Ischemic Heart Diseases) 12/2021 - 01/2013
9	Infarction (Infarctions) 12/2020 - 01/2013
7	Ischemia 01/2018 - 01/2013
6	Neoplasms (Cancer) 01/2022 - 03/2013
6	Brain Ischemia (Cerebral Ischemia) 12/2019 - 01/2014
4	Colitis 07/2022 - 10/2020
3	Wounds and Injuries (Trauma) 01/2019 - 01/2014
3	Myocardial Infarction 08/2017 - 06/2013
3	Hyperglycemia 01/2017 - 01/2015
3	Diabetic Cardiomyopathies 01/2017 - 01/2015
2	Experimental Arthritis 01/2022 - 01/2022
2	Colitis-Associated Neoplasms 01/2022 - 10/2020
2	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 07/2019 - 10/2018
2	Inflammation (Inflammations) 01/2019 - 11/2013
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2018 - 01/2013
2	Diabetes Mellitus 01/2018 - 12/2015
2	Stroke (Strokes) 01/2016 - 09/2014
1	Autoimmune Diseases (Autoimmune Disease) 01/2022
1	Esophageal Squamous Cell Carcinoma 01/2022
1	Coronary Disease (Coronary Heart Disease) 11/2021
1	Type 2 Diabetes Mellitus (MODY) 11/2021
1	Neoplasm Metastasis (Metastasis) 12/2020
1	Breast Neoplasms (Breast Cancer) 12/2020
1	Carcinogenesis 10/2020
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 12/2019
1	Sepsis (Septicemia) 01/2019
1	Brain Edema (Cerebral Edema) 01/2019
1	Brain Injuries (Brain Injury) 01/2019
1	Hypertension (High Blood Pressure) 01/2018
1	Vascular Diseases (Vascular Disease) 01/2018
1	Channelopathies 01/2018
1	Necrosis 08/2017
1	Fibrosis (Cirrhosis) 04/2017
1	Neuralgia (Stump Neuralgia) 10/2016
1	Hyperalgesia 10/2016
1	Hypersensitivity (Allergy) 10/2016

Drug/Important Bio-Agent (IBA)

6	AntioxidantsIBA 12/2019 - 02/2013
4	3,4-dihydroxyphenyllactic acidIBA 12/2021 - 01/2013
4	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2017 - 01/2015
3	Dextran SulfateIBA 07/2022 - 10/2020
3	Interleukin-6 (Interleukin 6)IBA 12/2020 - 11/2013
3	Neuroprotective AgentsIBA 12/2019 - 02/2015
3	Glucose (Dextrose)FDA LinkGeneric 12/2019 - 02/2013
3	Oxygen (Dioxygen)IBA 12/2019 - 02/2013
3	CytokinesIBA 01/2019 - 11/2013
3	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 08/2017 - 06/2013
2	tetrandrineIBA 01/2022 - 01/2021
2	EnzymesIBA 01/2022 - 11/2013
2	Sirtuin 1IBA 01/2019 - 12/2015
2	Calcium-Activated Potassium Channels (Calcium-Activated Potassium Channel)IBA 01/2018 - 01/2018
2	Malondialdehyde (Propanedial)IBA 08/2017 - 02/2013
2	Superoxide DismutaseIBA 08/2017 - 02/2013
2	hydroxysafflor yellow AIBA 04/2017 - 09/2014
2	4-hydroxy-2-nonenal (4-hydroxynonenal)IBA 01/2017 - 01/2014
2	protocatechualdehydeIBA 01/2017 - 06/2013
2	chikusetsu saponin IVaIBA 01/2016 - 12/2015
2	lithospermate BIBA 11/2013 - 02/2013
2	MB Form Creatine KinaseIBA 06/2013 - 01/2013
1	AlkaloidsIBA 01/2022
1	Acetyl Coenzyme A (Acetyl-CoA)IBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	norisoboldineIBA 01/2022
1	TriterpenesIBA 01/2022
1	madecassic acidIBA 01/2022
1	Interleukin-17 (Interleukin 17)IBA 01/2022
1	Amino Acids FDA Link 11/2021
1	OccludinIBA 01/2021
1	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amideIBA 01/2021
1	Estrogen ReceptorsIBA 12/2020
1	Tamoxifen FDA LinkGeneric 12/2020
1	Neutralizing AntibodiesIBA 12/2020
1	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2020
1	arctigeninIBA 10/2020
1	InflammasomesIBA 10/2020
1	AzoxymethaneIBA 10/2020
1	Fatty Acids (Saturated Fatty Acids)IBA 10/2020
1	AmidesIBA 12/2019
1	DystrophinIBA 07/2019
1	RNA Precursors (Precursor, mRNA)IBA 07/2019
1	Protective AgentsIBA 01/2019
1	buteinIBA 01/2019
1	Large-Conductance Calcium-Activated Potassium Channels (Maxi-K Channels)IBA 01/2018
1	CreatineIBA 08/2017
1	Proteins (Proteins, Gene)FDA Link 04/2017
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2017
1	8-Hydroxy-2'-DeoxyguanosineIBA 01/2017
1	GlycosidesIBA 01/2017
1	Protein Kinases (Protein Kinase)IBA 01/2017
1	FlavonoidsIBA 01/2017
1	butinIBA 01/2017
1	Pharmaceutical PreparationsIBA 10/2016
1	Paclitaxel (Taxol)FDA LinkGeneric 10/2016
1	fluorocitrateIBA 10/2016

Therapy/Procedure

3	Therapeutics 12/2020 - 03/2013
3	Ligation 01/2019 - 06/2013
1	Intraperitoneal Injections 07/2022
1	Oral Administration 01/2022
1	Punctures 01/2019
1	Drug Therapy (Chemotherapy) 10/2016